BioCentury
ARTICLE | Company News

AlphaRx, Cypress Bioscience deal

July 5, 2010 7:00 AM UTC

Cypress will return all rights for Indaflex to AlphaRx after a May decision to discontinue funding for development of the topical cream formulation of indomethacin. At the time, Cypress said it was not funding any of its proof of concept (POC) stage programs and that it was evaluating strategic transactions for development and commercial stage opportunities. Indaflex missed the primary endpoints in a Phase II trial to treat osteoarthritis (OA) in 2007. ...